H Javelot1, B Michel2, R Steiner3, T Javelot4, O Cottencin5. 1. Clinical Pharmacy Service - Mental Health Establishment (EPSAN), Brumath, France. 2. Faculté de Pharmacie - Laboratoire HuManiS (EA 7308), Service Pharmacie - CHU de Strasbourg, Strasbourg, France. 3. Service G06, Mental Health Establishment (EPSAN), Brumath, France. 4. Equipe de Liaison et de Soins en Addictologie, Centre Hospitalier Saint Jean de Dieu, Lyon, France. 5. Department of Psychiatry and Addiction Medicine, Fontan 2 Hospital, University Hospital of Lille, University of Lille, CHU de Lille, Lille, France.
Abstract
WHAT IS KNOWN AND OBJECTIVE: There is no consensus regarding treatment of catatonia and the main recent therapeutic progress has been the development of the zolpidem diagnostic and therapeutic test. We report on the use of this test in one of our patients. CASES SUMMARY: Mr. S. suffered from a paranoid schizophrenia. Three episodes of catatonia are described to illustrate the effect of zolpidem in a patient for whom lorazepam was ineffective or inadequate. WHAT IS NEW AND CONCLUSION: Zolpidem with appropriate testing appears to be a credible alternative to electroconvulsive therapy or increased lorazepam dosing and allows continuation of antipsychotic administration.
WHAT IS KNOWN AND OBJECTIVE: There is no consensus regarding treatment of catatonia and the main recent therapeutic progress has been the development of the zolpidem diagnostic and therapeutic test. We report on the use of this test in one of our patients. CASES SUMMARY: Mr. S. suffered from a paranoid schizophrenia. Three episodes of catatonia are described to illustrate the effect of zolpidem in a patient for whom lorazepam was ineffective or inadequate. WHAT IS NEW AND CONCLUSION: Zolpidem with appropriate testing appears to be a credible alternative to electroconvulsive therapy or increased lorazepam dosing and allows continuation of antipsychotic administration.